Malignant Pleural Mesothelioma Epidemiology summary

• In 2025, the total number of mesothelioma incident cases across the 7MM was nearly ~11,000 and the number of Malignant Pleural Mesothelioma cases were approximately 10,000. Malignant Pleural Mesothelioma is primarily caused by exposure to asbestos.
• Biomarker and histology-based testing is essential at diagnosis. Recommended tests include histologic subtyping (epithelioid, biphasic, sarcomatoid), immunohistochemistry (calretinin, WT1, CK5/6, BAP1, MTAP), and evaluation of ASS1 and MTAP/CDKN2A status to identify candidates for emerging targeted trials.
• In 2025, the US reported the highest number of Malignant Pleural Mesothelioma incident cases, totaling about 2,000, which accounts for approximately 22% of the 7MM.
• EU4 and the UK reported approximately ~2,600 epithelioid and mesothelioma, NOS/ NA cases each along with ~500 cases each for biphasic and sarcomatous Malignant Pleural Mesothelioma in 2025, figures that are expected to rise steadily through the forecast period (2026-2036).
• The epidemiology of Malignant Pleural Mesothelioma reflects a significant disease burden, driven by its aggressive nature, poor prognosis, and limited availability of curative options. Additionally, challenges in early diagnosis and non-specific symptom presentation often lead to delayed detection, further influencing reported incidence patterns and contributing to underestimation in certain regions.

DelveInsight’s "Malignant Pleural Mesothelioma Epidemiology Forecast – 2036" report delivers an in-depth understanding of Malignant Pleural Mesothelioma, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The Malignant Pleural Mesothelioma epidemiology report provides a comprehensive analysis of incident cases, capturing the annual number of newly diagnosed patients across the 7MM. It includes detailed segmentation by histological subtype, disease stage, age, and gender, along with regional distribution. The report evaluates historical and forecasted incidence trends (2026–2036), highlighting variations in disease occurrence and diagnosis patterns, and offering insights into the evolving burden of newly diagnosed Malignant Pleural Mesothelioma cases.

Malignant Pleural Mesothelioma DIsease Understanding

Malignant Pleural Mesothelioma Overview and Diagnosis

Malignant Pleural Mesothelioma is a rare and aggressive malignancy arising from the mesothelial cells lining the pleura, most commonly associated with prior asbestos exposure. The disease is characterized by diffuse tumor growth along the pleural surface, leading to progressive respiratory compromise, chest pain, and pleural effusion. Malignant Pleural Mesothelioma exhibits significant heterogeneity in histological subtypes, including epithelioid, sarcomatoid, and biphasic forms, each associated with varying prognosis and treatment response. The disease is typically progressive, with a poor overall survival rate.

Effective management of Malignant Pleural Mesothelioma requires a comprehensive and multidisciplinary approach. Diagnosis is based on a combination of clinical evaluation, imaging techniques such as CT and PET scans, and histopathological confirmation through biopsy to determine subtype and disease stage. Treatment strategies depend on disease stage and patient eligibility, and may include surgical resection, chemotherapy, immunotherapy, and multimodal approaches. The primary goals of management are to prolong survival, control disease progression, and improve quality of life, given the limited curative options currently available.

Further details are provided in the report...

Malignant Pleural Mesothelioma Unmet Needs

The section “unmet needs of Malignant Pleural Mesothelioma epidemiology” outlines the key gaps in understanding the true disease burden and incidence patterns. It highlights challenges faced in accurate case identification, reporting, and surveillance, and identifies areas for improvement in epidemiological assessment and data generation.

1. Need for improved incidence tracking and standardized reporting systems

2. Underdiagnosis and misclassification due to non-specific clinical presentation

3. Limited availability of robust, region-specific epidemiological data

4. Delays in diagnosis impacting accurate estimation of incident cases

and others…..

Note: Comprehensive unmet needs insights in Malignant Pleural Mesothelioma and their strategic implications are provided in the full report...

Malignant Pleural Mesothelioma Epidemiology

Key Findings from Malignant Pleural Mesothelioma Epidemiological Analysis and Forecast

• In 2025, the US reported approximately 1,500 male and 500 female cases of Malignant Pleural Mesothelioma, with these numbers expected to increase by 2036.
• According to DelveInsight’s estimates, there were approximately 6,000 incident cases of Malignant Pleural Mesothelioma across EU4 and the UK in 2025, with the number expected to rise by 2036.
• Within EU4 and the UK, Spain reported about 300 distant-stage Malignant Pleural Mesothelioma cases in 2025, the highest among other stages, highlighting the challenges of late-stage detection.
• In 2025, Japan recorded approximately 60% of distant Malignant Pleural Mesothelioma cases, 10% localized, and 15% cases for regional and unknown each, when categorized by stages.

Industry Experts and Physician Views for Malignant Pleural Mesothelioma

To keep up with Malignant Pleural Mesothelioma market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the Malignant Pleural Mesothelioma epidemiology, incidence trends, regional distribution, patient demographics, diagnostic rates, and real-world disease burden patterns in Malignant Pleural Mesothelioma, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 8+ KOLs to gather insights at country level. Centers such as the -     St. John’s University, Brigham and Women’s Hospital and Harvard Medical School, University of Liverpool, State University of New York Upstate Medical University, etc. were contacted.

Their opinion helps understand and validate Malignant Pleural Mesothelioma epidemiological trends, highlight key gaps in diagnosis and disease burden, provide deeper epidemiological context, and support strategic decisions for patient identification and disease monitoring in Malignant Pleural Mesothelioma.

Scope of the Malignant Pleural Mesothelioma Epidemiology Report

• The report covers a segment of key epidemiological highlights, an executive summary, and a descriptive overview of Malignant Pleural Mesothelioma, including its causes, risk factors, and factors influencing disease occurrence.
• Comprehensive insights are provided into incidence trends and forecasts, along with the future growth potential of diagnosis rates and evolving patterns of disease detection across the 7MM.
• Additionally, the report includes detailed segmentation of incident cases by histological subtype, age, gender, and region, offering a granular view of the epidemiological landscape.
• A thorough assessment of historical and forecasted incidence data, along with underlying assumptions and methodology, is included, providing a clear understanding of disease burden across the 7MM.
• The report provides strategic insights by highlighting trends in incidence, diagnostic gaps, and regional variations, supported by expert opinions and epidemiological analysis to better understand and project the Malignant Pleural Mesothelioma disease burden.

Malignant Pleural Mesothelioma Epidemiology Report Insights

• Malignant Pleural Mesothelioma incidence forecast, epidemiological burden, segmentation, trends, and opportunity assessment.

Malignant Pleural Mesothelioma Epidemiology Report Key Strengths

• Malignant Pleural Mesothelioma Epidemiology based (EPI   based) bottom up forecasting
• Artificial Intelligence (AI) enabled epidemiology research report
• 11-year forecast
• Malignant Pleural Mesothelioma epidemiological outlook (North America, Europe, Asia-Pacific)
• Malignant Pleural Mesothelioma Burden trends (by geography)

Malignant Pleural Mesothelioma Epidemiology Report Assessment

• Malignant Pleural Mesothelioma diagnostic trends
• Malignant Pleural Mesothelioma epidemiological gaps
• Malignant Pleural Mesothelioma development trends
• Malignant Pleural Mesothelioma emerging research focus
• Malignant Pleural Mesothelioma disease burden attractiveness
• Malignant Pleural Mesothelioma qualitative epidemiological insights

Access the Malignant Pleural Mesothelioma Market Insights Report through 2036 to understand disease burden, pipeline developments, competitive dynamics, and evolving treatment opportunities.

FAQs

• What was the Malignant Pleural Mesothelioma incident patient population and distribution (%) in 2025, and how will it evolve by 2036? What factors are driving these trends?
• What are the anticipated variations in incidence and diagnosis rates across different geographies?
• What will be the future diagnosis and epidemiological trends of Malignant Pleural Mesothelioma?
• What are the disease risks, burden, and key epidemiological gaps in Malignant Pleural Mesothelioma? What are the growth opportunities based on the patient population across the 7MM?
• How will changes in incidence and diagnosis impact the overall epidemiological landscape?
• What are the current diagnosis practices and epidemiology trends of Malignant Pleural Mesothelioma in the US, Europe, UK, and Japan?

Reasons to Buy Malignant Pleural Mesothelioma Epidemiology Report

• The report will help in developing strategies by understanding the latest trends and changing epidemiology of Malignant Pleural Mesothelioma.
• Bottom-up forecasting builds from the incident patient population, delivering a robust, data-driven epidemiological approach.
• Insights on patient burden/incidence, evolution in diagnosis, and factors contributing to changes in disease epidemiology during the forecast years.
• Understand the epidemiological opportunities across varying geographies and growth potential over the coming years.
• Identifying key trends in disease incidence will help anticipate shifts in the epidemiological landscape.
• Detailed analysis and segmentation of incident cases to provide visibility around high-burden patient groups.
• To understand KOLs’ perspectives on diagnosis challenges and gaps in disease identification.
• Detailed insights on epidemiological unmet needs to support improved disease tracking and diagnosis strategies.
• This Artificial Intelligence (AI)-enabled report summarizes complex epidemiological datasets into clear, actionable insights for stakeholders, investors, and healthcare providers.